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RelAtionshiP of vAsCulAR ComPliCAtions And 
exenAtide theRAPy fAiluRe in tyPe 2 diAbetiC 
PAtients 
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summARy – exenatide is an incretin mimetic that acts through glucagon-like peptide 1 re-
ceptor accepted as a successful novel glucose-lowering agent in type 2 diabetes. The aim of this study 
was to explore the possible predictive factors for exenatide efficacy among baseline characteristics of 
type 2 diabetic patients. We observed basic anthropometric measurements, laboratory findings and 
diabetic complications in ninety-one type 2 diabetic patients starting exenatide therapy. There were 
forty-six (50.5%) male and forty-five (49.5%) female patients, median age 58 (31-76) years, body 
mass index 38.95±4.35 kg/m2, duration of diabetes 10 (1-30) years and hbA1c level 8.3±1.4%. Thirty 
(33%) patients stopped therapy because of glycemic dysregulation during 105 (21-390) days on the-
rapy. These patients differed statistically significantly from those that continued therapy according 
to the following seven variables: higher fasting glucose blood concentration (11.5 mmol/l (5.6-20) 
vs. 10.2 mmol/l (5-19), higher serum creatinine concentration (93 µmol/l (44-149) vs. 72 µmol/l 
(44-124), more frequent diabetic complications including retinopathy (56.7% vs. 27.9%), chronic 
kidney disease (43.7% vs. 24.7%), coronary artery disease (53.3% vs. 31.1%) and peripheral artery 
disease (60% vs. 34.4%), and less often concomitant metformin and exenatide therapy (62% vs. 82%). 
bivariate logistic regression identified peripheral artery disease, coronary artery disease, retinopathy, 
and chronic kidney disease as risk factors for glycemic dysregulation on exenatide therapy. We found 
reasonable to consider that a higher rate of microvascular and macrovascular complications may 
indicate failure of exenatide therapy in the majority of patients. 
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Introduction
because of the rising trend in its incidence and 
prevalence, diabetes is one of the most challenging 
health problems worldwide. According to the in-
ternational diabetes federation, 366 million people 
had diabetes in 2011 (8.3% of the general population) 
and by the year 2030 it will have risen to 552 mil-
lion (9.9% of the population)1. type 2 diabetes mel-
litus (t2dm) accounts for more than 90% of these 
numbers. The progressive nature of the disease leads 
to the development of micro- and macrovascular com-
plications that are the main cause of comorbidities, 
which at long term result into enormous economic 
costs2. Although several classes of antidiabetic drugs 
are currently available, less than 50% of t2dm pa-
tients achieve and maintain glycosylated hemoglobin 
(hbA1c) <7% and only ~15% achieve target levels of 
glycemia, lipidemia and blood pressure together3. This 
may be due to the fact that the mechanisms of action 
of most antidiabetic agents are not based on reversal 
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of the main pathogenic disturbances of the disease, 
i.e. the triumvirate of insulin resistance in muscle and 
liver and pancreatic β cell failure4,5. Additionally, new 
findings suggest that adipose tissue, gastrointestinal 
tract, pancreatic α cells, kidney and brain together 
play an important role in the pathophysiological 
mechanism of t2dm progression6. because of these 
facts, innovative approaches to the treatment are con-
stantly being investigated and the incretin system 
compounds are currently the newest class of glucose 
lowering agents. The incretin mimetic exenatide was 
introduced in clinical practice several years ago and 
many experimental studies have shown that it might 
overcome previous therapy limitations acting through 
several different pathways7. exenatide is a synthetic 
peptide that shares 53% of amino acid sequence with 
glucagon-like peptide 1 (GlP-1), the incretin the im-
paired effect of which was found to be related to many 
pathophysiological abnormalities in t2dm8,9. it 
acts through GlP-1 receptor that is expressed in the 
brain, heart, pancreas, skeletal muscle, adipose tissue 
and liver in different forms10. According to several 
clinical trial based outcomes, exenatide increases the 
early and late phases of insulin secretion resulting in 
normalization of fasting and postprandial glycemia. 
Additionally, exenatide enhances insulin sensitivity, 
delays gastric emptying resulting in satiety and reduc-
es food intake, which leads to weight loss, improves 
fasting lipid profile, lowers blood pressure and has a 
cardioprotective effect11. These data suggest promis-
ing results in the future of t2dm metabolic control 
management. however, it has been noticed that every 
clinical study with exenatide has a certain number of 
dropouts due to hyperglycemia12-14. This advises that 
not all t2dm patients are suitable for this type of 
glucoregulation regimen. We decided to perform an 
open-label observational study in order to determine 
which basic factors may help us predict exenatide non-
responders, i.e. t2dm patients whose blood glucose 




This was a single-center open-label observational 
study performed at vuk vrhovac university Clinic 
for diabetes, endocrinology and metabolic diseases, 
Zagreb, Croatia. The primary objective of the study 
was comparison of baseline characteristics of two 
groups of t2dm patients: those who achieved nor-
malization of glycemia following their first injectable 
glucose-lowering therapy with exenatide and those 
who did not. exenatide was added to each patient’s 
current therapy regimen, so at study entry patients 
could be taking any oral antidiabetic agent. exenatide 
was started at a 5-µg twice daily dose and increased to 
10-µg twice daily, if needed. daily glucose monitor-
ing was required. Adverse events were assessed during 
hospital stay at therapy initiation or at each outpatient 
visit using a close-ended questionnaire. All patients 
gave their written informed consent before study en-
try.
Study participants
during the period of 14 months, i.e. from June 
2011 to August 2012, we studied 91 patients selected 
according to strict inclusion and exclusion criteria, out 
of the 93 patients who had started exenatide therapy. 
inclusion criteria were history of t2dm, hbA1c 
>7.5%, body mass index (bmi) >35 kg/m2, glomeru-
lar filtration rate ≥30 ml/min, absence of gallbladder 
stones and recent pancreatitis episode, and exenatide 
as first injectable glucose-lowering therapy. exclusion 
criteria were quitting exenatide therapy for any other 
reason except for glycemia dysregulation or gastroin-
testinal adverse events.
Study measurements
All subjects were studied in the morning after an 
overnight fast. basic anthropometric measurements 
were performed in all study subjects. blood pressure 
was measured twice in the sitting position with a 
mercury sphygmomanometer after a resting period of 
10 minutes and expressed in mm hg. fasting venous 
blood samples were collected in the morning between 
08:00 and 09:30 a.m. after an overnight fast for deter-
mination of complete blood count and biochemistry 
panel, lipid profile status, thyroid hormone status, se-
rum creatinine, glycated hemoglobin (hbA1c), fasting 
C peptide and C peptide in 120“, and insulin resistance 
determined by the homeostasis model Assessment 
(homA) index15. status of diabetic complications 
(retinopathy, chronic kidney disease (CKd), periph-
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eral and autonomic neuropathy, 
coronary artery disease (CAd) 
and peripheral artery disease) 
were established by specialist 
examination and additional di-
agnostic tests, if needed. CKd 
was defined as creatinine clear-
ance <60 mg/ml/min or albu-
minuria >300 mg/24 h from at 
least two 24-h urine samples. 
CAd was defined as a his-
tory of myocardial infarction or 
electrocardiogram (eCG) evi-
dence of ischemic heart disease. 
follow-up evaluation was based 
on three point self-reported glu-
cose profiles (morning, midday, 
evening) and seven point glu-
cose profiles during the hospital 
stay and later at 3- and 6-month 
outpatient visits. other vari-
ables were measured during the 
follow-up period and will be re-
ported in additional papers. 
Statistical analysis
statistical evaluation of 
data was carried out using 
sPss statistical package, ver-
sion 17.0 for Windows. base-
line data were reported using 
descriptive statistics. normal-
ity of distribution for continu-
ous variables was analyzed us-
ing Kolmogorov-smirnov test. 
normally distributed variables 
were described with mean and 
standard deviation (sd), while 
variables that were not normally 
distributed were described with 
median, minimum and maxi-
mum. nominal variables were 
reported with absolute numbers 
and percentages. to compare 
baseline characteristics of the 
two groups of patients we used 
parametric independent sample 

























t2dm duration (yrs) n=598 (0-30)
n=29
16 (4-24) 0.944
Weight (kg) n=59111 (86-168)
n=29
103 (78-148) 0.883









Pulse rate (beats/min) n=3976 (64-107)
n=25
74 (60-120) 0.642
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CRP (mg/l) n=424.0 (0.7-75)
n=25
4.4 (0.5-53.60) 0.769





















Ast (units/l) n=5925 (14-53)
n=28
21 (13-56) 0.654
Alt (units/l) n=5736 (15-89)
n=28
24.5 (8-68) 0.100
GGt (units/l) n=5839.5 (19-118)
n=27
28 (14-149) 0.538
AP (units/l) n=5885 (30-131)
n=27
85 (39-126) 0.809





















homA = homeostatic model assessment; CRP = C-reactive protein; 
Ast = aspartate transaminase; Alt = alanine transaminase; GGt = gamma-
glutamyltransferase; AP = alkaline phosphatase; tsh = thyroid-stimulating hormone
t-test for continuous variables and its 
corresponding nonparametric alterna-
tive mantel-haenszel or χ2 test for cat-
egorical variables. using variables that 
were statistically significant (p<0.05, 
p<0.1) at the between-group compari-
son level, the bivariate logistic regres-
sion model was employed to determine 
the baseline factor odds ratio of failure 
in exenatide therapy. The significance 
was considered at the level of p<0.05.
Results
Patient disposition, baseline 
demographic and clinical characteristics
ninety-three patients received ex-
enatide therapy during the observed 
period; two were excluded from the 
study because they stopped therapy 
for other reasons than poorly regulated 
blood glucose levels: one because of per-
sistent gastrointestinal adverse events 
and another one arbitrarily. out of 
91 analyzed patients, 46 (50.5%) were 
male and 45 (49.5%) female, median 
age 58 (31-76) years, bmi 38.95±4.35 
kg/m2, duration of diabetes 10 (1-
30) years and hbA1c level 8.3±1.4%. 
Thirty (33%) patients stopped therapy 
because of glycemic dysregulation dur-
ing 105 (21-390) days on therapy. 
Differences between the groups of drug 
responders and drug nonresponders by 
univariate analysis
The following seven variables dif-
fered statistically significantly be-
tween the two groups of patients, i.e. 
drug responders (n=61), who achieved 
and maintained blood glucose con-
trol, and drug nonresponders (n=30): 
fasting blood glucose concentration 
(p=0.032), serum creatinine concen-
tration (p=0.031), incidence of retin-
opathy (p=0.009), CKd (p<0.001), 
CAd (p=0.042), peripheral artery 
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disease (p=0.017) and concomitant therapy with 
metformin and exenatide (p=0.04) (tables 1-4). The 
group of nonresponders had a higher fasting glucose 
blood concentration (11.5 mmol/l (5.6-20) vs. 10.2 
mmol/l (5-19)) and higher serum creatinine concen-
tration (93 µmol/l (44-149) vs. 72 µmol/l (44-124)). 
nonresponders more frequently showed diabetic com-
plications including retinopathy (56.7% vs. 27.9%), 
CKd (43.7% vs. 24.7%), CAd (53.3% vs. 31.1%) and 
peripheral artery disease (60% vs. 34.4%). The group 
of patients who achieved and maintained blood glu-
cose level control on exenatide therapy more often had 
concomitant metformin and exenatide therapy (82% 
vs. 62%). 
Logistic regression
defining the covariates by variables shown statis-
tically significant (p<0.1) by univariate analysis and 
therapy outcome as a dependent variable, we applied 
bivariate logistic regression. The significant risk was 































































disease, CAd, retinopathy and CKd. Peripheral ar-
tery disease increased the risk of exenatide therapy 
failure by 42.2%, CAd by 39.6%, retinopathy by 
29.5% and CKd by 4.7% (table 5).
Discussion
since twice daily subcutaneous injection of ex-
enatide has a power of lowering hbA1c by about 
0.5%-1%, the AdA/eAsd consensus on treatment 
options for t2dm patients finds it appropriate ther-
apy for patients with glycemic control above target 
levels as well as monotherapy or in combination with 
sulfonylurea, metformin and/or thiazolidinediones16. 
in fact, several clinical trials have proven its efficacy in 
achieving glucoregulation in type 2 diabetic patients. 
heine et al. as well as Pawaskar et al. found it equal-
ly or more effective as insulin glargine injection in 
achieving and sustaining glycemic control in patients 
with poorly regulated diabetes17,18. A pilot study per-
formed by davis et al. suggests that it was feasible to 
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sustain glycemic control when substituting insulin with exenatide19. 
yet, it is important to note that in all clinical trials with exenatide, a 
certain number of patients failed to achieve or maintain target blood 
glucose levels12-14. Although a consistent body of literature suggest 
that GlP-1 secretion is impaired in t2dm patients, recent studies 


































































































RAAs = renin angiotensin aldosterone system inhibitors; hmG-CoA reductase 
inhibitors = 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
t2dm patients and healthy individuals 
are not as apparent, i.e. the decrement in 
GlP-1 levels is not a general character-
istic of t2dm patients, and that there 
are many individual factors significantly 
related to GlP-1 secretory response20. 
Thus, therapy with incretin-based glu-
cose lowering medications including 
exenatide may not be suitable for all 
t2dm patients.
in this study, we compared clinical 
and laboratory parameters between ex-
enatide therapy responders and nonre-
sponders in order to identify the factors 
that might possibly predict treatment 
failure. our findings suggested that pa-
tients who did not respond to exenatide 
therapy showed a higher prevalence of 
retinopathy, CKd, CAd and peripher-
al artery disease, i.e. microvascular and 
macrovascular complications, compared 
to the cohort of exenatide responders. 
As persistent hyperglycemia and hyper-
insulinemia lead to development of mi-
crovascular and macrovascular compli-
cations, we find it reasonable to consider 
that the presence of microvascular and 
macrovascular complications in t2dm 
patients emphasizes longer disease du-
ration or higher blood glucose levels for 
a longer period of time. together with 
not significant but still worse fasting lip-
id profile in the nonresponder group, it 
may exert a glucotoxic as well as lipotoxic 
action and subsequently lead to greater β 
cell exhaustion. Additionally, although 
not shown as statistically significant, 
the group of nonresponders were older 
and had longer disease duration. They 
also had slightly higher fasting glucose 
levels and hbA1c levels, while lower 
both fasting and 120“ C peptide levels 
in comparison to the responder group. 
These findings indicated the presence 
of lower endogenous basal insulin lev-
els and lower postprandial endogenous 
insulin levels as well. That might con-
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tribute to the confirmation of exenatide insulinotropic 
effect as its main glycemic management action path-
way. Additionally, Andersen et al. also showed the 
higher baseline hbA1c level to be a good predictor 
in identification of exenatide responders21. however, 
buysschaert et al. found the exenatide therapy regi-
men to be effective independently of baseline hbA1c 
levels, weight, bmi, age and duration of diabetes22. 
like defronzo et al., we also found a higher rate of 
exenatide/metformin dual therapy in the group of re-
sponders12. We explain it by the fact that metformin 
enhances insulin sensitivity, and the combination of 
two different therapeutic pathways usually manage to 
sustain feasible glycemia control. 
higher diastolic blood pressure and higher serum 
creatinine levels in our nonresponder group may indi-
cate more severe CKd that may lead to higher activity 
of the circulating GlP-1 degradation enzyme dipep-
tidyl peptidase-4 (dPP4), which is already elevated 
in hyperglycemia state23,24. in fact, dPP4 has recently 
been identified as a novel adipokine that impairs in-
sulin signaling in three different primary cell types: 
adipocytes, skeletal muscle and smooth muscle cells25. 
This finding potentially links elevated dPP4 levels to 
the higher rate of insulin resistance, which cannot be 
overcome by exenatide insulinotropic effect. We did 
not perform dPP4 plasma levels or dPP4 plasma ac-
tivity analysis in our study and did not find statistical-
ly significant difference in insulin resistance between 
the two groups of patients. however, it is important 
Table 5. Bivariate logistic regression analysis
oR P value 95% Ci
Peripheral artery 
disease 0.426 0.05 0.222-0.818
Coronary artery 
disease 0.396 0.04 0.183-0.856
Retinopathy 0.295 0.009 0.095-0.921
Chronic kidney 
disease 0.047 <0.001 0.001-0.164
metformin with 
exenatide 2.456 0.056 0.669-9.01
serum creatinine 
level 1.042 0.015 0.964-1.126
fasting glucose level 1.076 0.287 1.059-1.092
to note that we had approximately 1/3 of missing data 
in each group for this variable, which gives the pos-
sibility of irrelevant result. however, dPP4 levels in 
t2dm patients both with and without vascular com-
plications represent a highly significant area for fur-
ther study evaluation.
in conclusion, we found it reasonable to consider 
that a higher rate of microvascular and macrovascu-
lar complications in nonresponder group might reflect 
exhausted reservoirs of endogenous insulin and those 
complications may be a good predictor of failure of ex-
enatide therapy in the majority of patients. however, 
whether detection of a higher rate of chronic compli-
cations in t2dm has a predictive value for efficacy of 
GlP-1 based therapy needs to be assessed in further 
follow-up studies.
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sažetak
PoveZAnost vAsKulARnih KomPliKACiJA s iZostAnKom teRAPiJsKoG učinKA 
eKsenAtidA u bolesniKA sA šećeRnom bolešću tiPA 2 
K. Blaslov, K. Zibar, T. Bulum i L. Duvnjak
eksenatid je inkretinski mimetik koji djeluje putem receptora proteina nalik glukagonu 1, široko prihvaćen kao uspje-
šan novi lijek u terapiji šećerne bolesti tipa 2. svrha ovoga istraživanja bila je istražiti moguće čimbenike predviđanja 
učinkovitosti terapije analizom osnovnih nalaza među bolesnicima sa šećernom bolešću tipa 2. Provedena je analiza an-
tropometrijskih obilježja, laboratorijskih nalaza i evaluacija dijabetičnih komplikacija kod 91 bolesnika koji su započeli 
terapiju eksenatidom. bilo je 46 (50,5%) bolesnika muškog spola i 45 (49,5%) ženskog spola; medjian dobi bio je 58 (31-76) 
godina, indeks tjelesne mase 38,95±4,35 kg/m2, trajanje šećerne bolesti 10 (1-30) godina s prosječnom vrijednosti hbA1c 
8,3±1,4%. tridesetoro (33%) bolesnika prekinulo je terapiju zbog loše regulacije glikemije tijekom 105 (21-390) dana. 
sedam varijabli statistički ih je razlikovalo od skupine koja je postigla zadovoljavajuću glukoregulaciju na eksenatidu: više 
vrijednosti glukoze natašte (11,5 mmol/l (5,6-20) prema 10.2 mmol/l (5-19), više vrijednosti kreatinina u serumu (93 
µmol/l (44-149) prema 72 µmol/l (44-124), viša učestalost razvijenih dijabetičnih komplikacija: retinopatije (56,7% pre-
ma 27,9%), kronične bubrežne bolesti (43,7% prema 24,7%), koronarne arterijske bolesti (53,3% prema 31,1%) i periferne 
arterijske bolesti (60% prema 34,4%), te rjeđa upotreba metformina u kombinaciji s eksenatidom (62% prema 82%). biva-
rijatna logistička regresija identificirala je perifernu arterijsku bolest, koronarnu arterijsku bolest, retinopatiju i kroničnu 
bubrežnu bolest kao statistički značajne čimbenike rizika za disregulaciju glikemije na terapiji eksenatidom. navedeni 
rezultati navode na zaključak kako bi razvijene mikrovaskularne i makrovaskularne komplikacije mogle biti čimbenik koji 
predviđa neuspjeh glukoregulacije eksenatidom.
Ključne riječi: Eksenatid, glukagonu sličan peptid 1; Dijabetes melitus, tip 2; Vaskularne komplikacije, dijabetične  
